DOCSLIB.ORG

Prospectus Symp19-8-2019.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS TH INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM NOVEMBER 7-9, 2019 NEW YORK, NY MOUNTSINAIUROLOGYCME.ORG HIGHLIGHTS • Over 100 world-renowned faculty • Engaging point-counterpoint debates and • Live 3-D surgical demonstrations, including panel discussion prostate, kidney, bladder procedures • Global exposure with international web streaming of select sessions and events Welcome to the Fourth International Prostate Cancer and Urologic Oncology Symposium. EDUCATIONAL HIGHLIGHTS • Live 3-D surgery transmission covering complex urologic surgery • Comprehensive didactic lectures from the world’s leading experts in urologic oncology • Robust review of the latest advances in surgical techniques and management of prostate, kidney, and bladder cancer • Personal interaction with world-class faculty • Stimulating point-counterpoint debates on timely topics DAILY HIGHLIGHTS PROSTATE DAY 1 THUR. 11/7/19 PROSTATE DAY 2 FRI. 11/8/19 KIDNEY & BLADDER SAT. 11/9/19 • Advanced imaging in genomics • Innovations in the management of • New progress in pre-operative and for prostate cancer castrate-sensitive prostate cancer intra-operative imaging, 3-D • Biomarkers and immunotherapy modelling, and ultra sound • Focus on radiomics and guidance for renal tumors radiogenomics • Update on clinical trials for castrate-resistant treatments for • Novel therapeutics in the • Utility of imaging and artificial prostate cancer management of metastatic renal intelligence in prostate cancer cell carcinomas: VEFG, TKIs, and treatment • Advances in multi-modal immunotherapy treatments for locally advanced • Targeted biopsy and focal therapy prostate cancer • Genomics and biomarkers for options for prostate cancer kidney and bladder cancer • 3-D robotic technique for nerve • Urinary incontinence and sexual sparing • Advances in second line function post-operative treatment transitional cell carcinoma for • Status of bio tech and clinical trials bladder and kidney • Improvements in imaging and in prostate cancer treatment targeted therapy for metastatic • Improvement in surgical technique cancer • Highlights from ASCO and AUA on to maximize outcome for kidney metastatic prostate cancer and bladder cancer • New techniques to improve out- comes for robotic prostatectomy • Discussion of single port robotic surgery • Clinical trials in nerve sparing and nerve regeneration after prostate cancer surgeries A full agenda will be available on our symposium website shortly. A full agendPlease a will feel be free available to reference shortly. the Please 2018 agenda feel free on to pages reference 10-20, last year’s which willagenda be similar on pages to the 10-20.2019 program. 2 | MOUNTSINAIUROLOGYCME.ORG NOVEMBER 7 – 9, 2019 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS DIRECTOR: ASH TEWARI, MBBS, MCH, FRCS (Hon.) Professor and Chairman of the Department INVITATION of Urology Department of Urology TO EXHIBIT/SPONSOR [email protected] CO-DIRECTOR: Dear Industry Colleagues: KETAN BADANI, MD Professor of Urology and Vice Chairman of the Department of Urology On behalf of the Department of Urology at the Icahn School of Medicine at Mount Department of Urology Sinai in New York City, I am thrilled to invite you to participate in the Fourth [email protected] International Prostate Cancer and Urologic Oncology Symposium set for November 7-9, 2019 in New York! This year’s program is our most innovative yet, PLANNING COMMITTEE: complete with over 100 world-renowned experts who will provide in-depth training NINA BHARDWAJ, MD, PhD on cutting-edge medical advances and ground-breaking treatment approaches for Professor of Medicine, Hematology, prostate, kidney, bladder, and renal cell cancers. There will also be a unique focus this and Medical Oncology Department of Medicine, Hematology, and year on critical issues in immuno-oncology and sexual health, as well as multiple live Medical Oncology surgeries and focused demonstrations. Ranked among the nation’s best for Urology [email protected] in the “Best Hospitals” issue of U.S. News & World Report, the physicians of Mount Sinai Urology are leaders in robotic surgery and minimally invasive procedures to CARLOS CORDON-CARDO, MD, PhD Professor and Chairman treat prostate, kidney, and bladder cancers. Join the Mount Sinai Department of of the Department of Pathology Urology for an interactive symposium with 3-D demonstrations of the latest robotic Department of Pathology surgery techniques for prostate, kidney and bladder cancer. Directed by the world’s [email protected] leading robotic experts and taught by an internationally renowned faculty, attendees MATTHEW GALSKY, MD gain emerging and practical tools to optimize their robotic surgery skills. We are Professor of Medicine, Hematology, and Medical Oncology also on the forefront of diagnosis and treatment for urinary tract conditions, kidney Department of Medicine, Hematology, and stones, infertility, erectile dysfunction, female pelvic medicine, and pediatric urologic Medical Oncology conditions. [email protected] As you will see in the enclosed Partnership Prospectus, we are offering several MANTU GUPTA, MD, FRCS (Glasg) Professor of Urology sponsorship and exhibitor opportunities for this year’s program, to help you gain Department of Urology access to, and inform, symposium attendees about your company, your research [email protected] development program and your marketed products. We expect over 500 attendees ADAM MARGOLIN, PhD at this year’s program, including physicians, nurses, pharmacists, and researchers, all Professor and Chairman of whom will be actively engaged in discussions across the prostate and urological of the Department of Genetics and Genomic Science cancer landscape. Department of Genetics and Genomic Science Affiliating with the Fourth International Prostate Cancer and Urologic Oncology [email protected] Symposium is the most direct route in meeting and sharing your products with some WILLIAM OH, MD of the most well-known, respected health care providers and decision makers in the Professor of Medicine, Hematology, urologic community. As an essential part of the symposium, you will be able to make and Medical Oncology invaluable connections with key opinion leaders, academic researchers and other Department of Medicine, Hematology, and Medical Oncology industry stakeholders as we continue the tradition of advancing the level of science [email protected] and quality of care in prostate and urologic oncology. MICHAEL PALESE, MD To this end, I invite you to review the attached Partnership Prospectus to learn Professor of Urology more about the program and to find out how to reserve your prime exhibit space Department of Urology today. More information can be found at mountsinaiurologycme.org. If you have [email protected] any questions, please contact Ms. Jennifer Berens at 425-442-13140 or via email at ERIC SCHADT, PhD Dean of Precision Medicine, Professor of [email protected]. We look forward to having you as our industry partner Genetics and Genomic Science for this year’s program! Department of Genetics and Genomic Science Sincerely, [email protected] BACHIR TAOULI, MD Professor of Radiology Department of Radiology [email protected] Ash Tewari, MBBS, MCh, FRCS (Hon.) Professor, Icahn School of Medicine at Mount Sinai Kyung Hyun Kim, MD, Chair of the Department of Urology Chair, Milton and Carroll Petrie Department of Urology, Mount Sinai Health System MOUNTSINAIUROLOGYCME.ORG | 3 • 2017 •• 2018 ••• FACULTY Ronney Abaza MD, FACS Ohio Health Dublin Alexander Haese MD Martini-Clinic Prostate Vipul Patel MD, FACS Florida Hospital Cancer Methodist Hospital Cancer Center, Hamburg, Germany Institute Urologic Oncology Program Mutahar Ahmed MD Hackensack University Misop Han MD Johns Hopkins School of Peter Pinto MD National Cancer Institute Medical Center, New Jersey Center for Medicine Urologic Oncology Branch Prostate Cancer & Urology Stefanie Hectors PhD Mount Sinai - Icahn Francesco Porpiglia MD San Luigi Gonzaga Olof Akre MD Mount Sinai - Department School of Medicine Hospital, University of Turin of Urology/Karolinska Institutet Ashok Hemal MD Wake Forest Baptist Health - James Porter MD Swedish Urology Group Walter Artibani MD University Hospital Institute for Regenerative Medicine Isaac Powell MD Wayne State University Verona, Italy Michael Herman MD South Nassau Surgical Sciences Ketan Badani MD Mount Sinai - Department Communities Hospital Rajveer Purohit MD Mount Sinai -Department of Urology Markus Hohenfellner MD University Hospital of Urology Mitchell C. Benson MD Columbia University Heidelberg Department of Urology Ganesh Raj MD, PhD UT Southwestern Medical Medical Center Jim Hu MD, MPH Weill Cornell Medicine Center Department of Urology Thomas Bessede MD CHU Bicetre, Bicetre Simon Hughes PhD King’s College London Abhay Rane OBE, MS, FRCS, FRCS (Urol) East Surrey Pari-South University John Isaacs PhD Johns Hopkins School of Hospital, United Kingdom Jerry Blaivas MD Mount Sinai - Department Medicine Art Rastinehad DO Mount Sinai - Department of Urology Jihad Kaouk MD Cleveland Clinic - Department of Urology Maurizio Buscarini MD Universita Campus of Urology Amanda Rhee MD Mount Sinai - Department Bio-Medico di Roma Steven Kaplan MD Mount Sinai - Department of Anesthesiology, Perioperative & Pain Umberto Capitanio MD San Raffaele Hospital of Urology Medicine Milan, Italy Deepak
Recommended publications
  • In the News September 30, 2016

    In the News September 30, 2016

    From: ITNDaily on behalf of Werle, Laura Subject: Mount Sinai In the News - September 30, 2016 Date: Friday, September 30, 2016 2:06:09 PM Attachments: ATT00002.txt In the News September 30, 2016 Nature – September 30 Inflammation in Patients With Cushing Disease — Claire Greenhill Circulating levels of proinflammatory cytokines are increased in patients with Cushing disease, both during active disease and after remission, according to new data published in Clinical Endocrinology. These findings demonstrate that cytokine levels are increased in patients after remission of Cushing disease, which could explain the persistent increased risk of cardiovascular-related death. The study, led by Eliza Geer, MD, a professor of endocrinology at the Icahn School of Medicine at Mount Sinai, notes that more studies are needed to determine why levels of IL-6 and IL-1β remain elevated after remission of Cushing disease. - Eliza Geer, MD, Associate Professor, Medicine, Endocrinology, Diabetes and Bone Disease, Neurosurgery, Icahn School of Medicine at Mount Sinai Learn more: http://www.nature.com/nrendo/journal/vaop/ncurrent/full/nrendo.2016.170.html WCBS – September 29 ‘Artificial Pancreas’ Expected To Make Life Easier, Healthier For Type 1 Diabetes Patients — Max Gomez A groundbreaking new device could change the lives of millions of people living with diabetes. Federal regulators just approved an artificial pancreas that can monitor and administer insulin. The key is a computer algorithm that does those calculations faster and more accurately than a patient can. “It looks at the numbers from a moment to moment basis, and it will proactively predict what is going to happen next and make clinical decisions that cannot be done at that rate.
  • At Newyork-Presbyterian Hospital/Weill Cornell Medical Center

    At Newyork-Presbyterian Hospital/Weill Cornell Medical Center

    Cancer Service Directory Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center Cancer Service Directory 1 Weill Cornell Medical College – Full Time Faculty Table of Contents: Bone Marrow & Stem Cell Transplantation 2 Brain & Spinal Tumors 2 Breast Cancer 3 Gastrointestinal Cancers 4 Gynecologic Oncology 8 Comprehensive Cancer Head & Neck Cancer 9 Interventional Radiology 10 Care and Clinical Research Leukemia, Myeloproliferative and Bone Marrow at NewYork-Presbyterian Failure Program 11 Lymphoma 12 Weill Cornell Medical Center Multiple Myeloma 13 Melanoma/Skin Cancer 13 Non-Malignant Hematology 14 Pediatric Cancer 15 Radiation Oncology 16 Reconstructive Microsurgery after Cancer Surgery 17 Supportive Care for the Oral Effects of Cancer Treatment 17 Thoracic Cancers 17 Urologic Cancers 18 2 Cancer Service Directory The Weill Cornell Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center provides world-class cancer care informed by vigorous clinical and translational research. Our dedicated cancer experts are constantly engaged in leading-edge clinical research so that we can offer patients the most innovative cancer treatments and therapies available. Although advancing the future of cancer treatment is a major focus, our team is also equally committed to providing patients with personalized, compassionate care in a supportive, healing environment. Cancer care, research and education are offered through several renowned specialty centers: the Breast Center at the Iris Cantor Women’s Center; the Center for Lymphoma and Myeloma; the NewYork-Presbyterian Phyllis and David Komansky Center for Children’s Health; the Center for Advanced Digestive Care and the Jay Monahan Center for Gastrointestinal Health; the Division of Hematology and Medical Oncology; and the Departments of Surgery, Neurosurgery, Radiation Oncology, Radiology and Urology.
  • PROGRAM BOOK & ABSTRACTS Table of Contents

    PROGRAM BOOK & ABSTRACTS Table of Contents

    15th Annual Meeting of the Society of Urologic Oncology Extraordinary Opportunities for Discovery December 3 – 5, 2014 Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland PROGRAM BOOK & ABSTRACTS TABLE OF CONTENTS Board of Directors 2014 – 2015 .................................................................................................................2 Committees .................................................................................................................................................3 2014 Faculty Listing ...................................................................................................................................4 Promotional Partners and Contributors ...................................................................................................6 Exhibitors ....................................................................................................................................................7 Industry Sponsored Symposia ..................................................................................................................8 General Meeting Information ...................................................................................................................10 Educational Needs and Objectives ......................................................................................................... 11 Accreditation Information ........................................................................................................................13
  • 2017 Annual Report Lewis C. Cantley, Ph.D

    2017 Annual Report Lewis C. Cantley, Ph.D

    2017 Annual Report Lewis C. Cantley, Ph.D. Meyer Director Translating basic science discoveries into clinical applications that change the standard of care for cancer patients is the central mission of the Sandra and Edward Meyer Cancer Center. In the past year, we have continued to strengthen the support we provide to our members through programs and resources that will broaden our impact in basic science, translational research and patient care. Leadership Leadership is a critical component of an effective organization, and the Meyer Cancer Center senior leadership team provides strategic direction and oversight in the areas of basic science, clinical research, clinical care and administration. • John Blenis, Ph.D., Associate Director of Basic Science, oversees the direction of basic science research programs, as well as the Collaborative Research Initiative, the annual Meyer Cancer Center pilot grant program. • Julie L. Boyer, Ph.D., Associate Director of Administration, supports all aspects of cancer center strategic development and provides oversight for cancer center initiatives and resources. • Andrew Dannenberg, M.D., Associate Director of Cancer Prevention, provides recommendations on program development in population sciences. • Howard A. Fine, M.D., Associate Director of Translational Research, has responsibility for facilitating collaborations between basic scientists and clinical researchers. • Silvia Formenti, M.D., Associate Director of Radiation Oncology, integrates the efforts of our growing immunotherapy program on the continuum from basic science through clinical practice. • John P. Leonard, M.D., Associate Director of Clinical Research, facilitates a robust clinical trials operation, ensuring that our clinical trial portfolio meets the metrics for an NCI-designated cancer center. • David M.
  • In the News July 29, 2016

    In the News July 29, 2016

    From: ITNDaily on behalf of Stephanie Sherman Subject: Mount Sinai In The News - July 29, 2016 Date: Friday, July 29, 2016 11:20:39 AM Attachments: ATT00002.txt In the News July 29, 2016 WBUR News – July 28 Doctors Need A New Skill Set For This Opioid Abuse Treatment — Karen Shakerdge Braeburn Pharmaceuticals, the company behind the newly FDA-approved treatment Probuphine, is teaching doctors how to use it. Although addiction specialists welcome Probuphine, which delivers a constant dose of the drug buprenorphine over six months, at this early stage it's complicated for physicians to add it to their repertoire. Patients using Probuphine were 14 percent more likely to stay opioid-free compared to those using a daily sublingual version of buprenophine, according to a study published this month in JAMA, the Journal of the American Medical Association. So it's good to have another way to deliver medication-assisted treatment, says Richard Rosenthal, medical director of addiction psychiatry for the Mount Sinai Health System. Rosenthal was one of two principal investigators on a Probuphine clinical trial. "Everybody is waking up to the fact that we're in the midst of an opioid epidemic," says Rosenthal. "There are actually very few medications for addiction of any kind. Given the addiction treatment system in the United States, most of the treatment that's given is psychosocial. There's very little use of FDA-approved medications." - Richard N. Rosenthal. MD, Professor, Psychiatry, Mount Sinai West Learn more: http://www.wbur.org/npr/487080738/doctors-need-a-new-skill-set-for-this-opioid-abuse- treatment MD Alert – July 28 Some Non-Celiac Gluten Sensitivity Patients May Have 'Celiac Lite' Disease — Marilynn Larkin A subset of patients with non-celiac gluten sensitivity (NCGS) may actually have a form of celiac disease, researchers in Spain report.
  • PARTNERSHIP PROSPECTUS SEPTEMBER MOUNT SINAI HOSPITAL 7-9 NEW YORK, NEW YORK 2017 Second International Urologic Cancer Symposium

    PARTNERSHIP PROSPECTUS SEPTEMBER MOUNT SINAI HOSPITAL 7-9 NEW YORK, NEW YORK 2017 Second International Urologic Cancer Symposium

    EXHIBITOR AND PROMOTIONAL PARTNERSHIP PROSPECTUS SEPTEMBER MOUNT SINAI HOSPITAL 7-9 NEW YORK, NEW YORK 2017 Second International Urologic Cancer Symposium HIGHLIGHTS • Over 80 renowned global faculty • Live 3D surgical demonstrations, including prostate, kidney, bladder and reconstruction • Point-Counterpoint Debate • Annual Push Up Challenge • Gala to Raise Funds for Urologic Cancer Research TOPIC AREAS • Screening and Low Risk Disease • Localized Prostate Cancer • Biomarkers and Genomics • Advanced Prostate Cancer • Immunotherapy • Kidney Cancer • Focal Therapy • Bladder Cancer www.mountsinaiurologycme.org TABLE OFCONTENTS Invitation to Exhibit/Sponsor . 1 Department of Urology 75th Anniversary Session . 2 Screening & Low Risk Disease . 3 Focal Therapy . 4 Treatment Failure . 4 Immunotherapy & Tumor Microenvironment . 5 Radical Prostatectomy . 6 Treating Localized Disease . 7 Advanced Prostate Cancer . 8 Locally Advance Disease. 9 Quality of Life . 9 Kidney Cancer - I. 10 Kidney Cancer - II . 11 Kidney Cancer - III . 12 Bladder Cancer I . 13 Partnership Information . 14 Partnership Opportunities . 15 Exhibit Registration Form . 17 Agenda. 18 Invitation to Exhibit/Sponsor 1 Course Director Dear Industry Colleagues: Ash Tewari, MBBS, MCh On behalf of the Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in New York City, I Co –Directors would like to invite you to partner with the 2nd International Urologic Cancer Symposium being held on September On behalf of the Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in New Ketan K. Badani, MD 6-9, 2017 at the Mount Sinai School of Medicine in New York, NY. Ranked among the nation’s best for Urology York City, I would like to invite you to partner with the Second International Prostate Cancer Nina Bhardwaj, MD, PhD in the 2016-2017 "Best Hospitals" issue of U.S.
  • Curriculum Vitae [PDF]

    Curriculum Vitae [PDF]

    CURRICULUM VITAE GYAN PAREEK, M.D. Academic Address: 2 Dudley Street, Suite 174 Providence, RI 02905 Academic Telephone Number: 401-444-8570 Academic Fax Number: 401-444-6947 Mobile Number: 401-537-7763 Electronic Mail Address: [email protected] EDUCATION Undergraduate: University of Pittsburgh, Pittsburgh, PA Bachelor of Science in Neuroscience, 1991 Graduate: Roswell Park Cancer Institute, SUNY at Buffalo Buffalo, NY Master of Science, 1993 Brown University Providence, RI Master of Arts ad eundem, 2014 Harvard Medical School Boston, MA 2018-Current Harvard Certificate in Leadership Medical School: St. George’s University School of Medicine, M.D., 1998 POSTGRADUATE TRAINING Residency: Lenox Hill Hospital, New York, NY Surgery (PGY1), 7/1/1998-6/30/1999 Lenox Hill Hospital, New York, NY Surgery (PGY2), 7/1/1999-6/2000 Lenox Hill Hospital, New York, NY Urology, 7/1/2000-6/30/2004 Fellowship: Laparoscopy and Endourology, University of Wisconsin, Madison, WI Clinical Instructor, 7/1/2004-6/30/2005 1 POSTGRADUATE HONORS AND AWARDS 2004 American Urological Association Pfizer Scholar 2005 Annual Essay Contest, Second Place, “Basic Science” and “Elastographic Measurements of In-Vivo Radiofrequency Ablation Lesions of the Kidney.” Endourological Society, Amsterdam, Netherlands 2006 Urology (Gold Journal) Essay Contest, Second Place, “Shockwave Lithotripsy Success Based on Skin to Stone Distance on Computed Tomography.” American Urological Association, Atlanta, Georgia 2009 The Dean’s Excellence in Teaching Award, “Urology Clinical Elective”,
  • Douglas S. Scherr 2. Office A

    Douglas S. Scherr 2. Office A

    Weill Cornell Medical College Curriculum vitae and Bibliography A. GENERAL INFORMATION 1. Name: Douglas S. Scherr 2. Office address, telephone, fax: Starr 900, Department of Urology The New York Presbyterian Hospital- Weill Medical College of Cornell University 525 East 68th Street New York, NY 10065 Phone: (212) 746-5788 Fax: (212) 746-0975 3. Email: [email protected] B. EDUCATIONAL BACKGROUND 1. Degrees Degree Institution Dates attended Year awarded B.A. Cornell University, Arts & Sciences 8/85-5/89 1989 Ithaca, New York M.D. The George Washington University 7/90-6/94 1994 Medical School Washington, D.C. C. PROFESSIONAL POSITIONS AND EMPLOYMENT Post-doctoral training: 1994-5 Intern, General Surgery The George Washington University Hospital 1995-6 Junior Assistant Resident, General Surgery The George Washington University Hospital Resident in Urology The James Buchanan Brady Department of Urology The New York Hospital-Cornell Medical Center New York, N.Y. 1999-00 Chief Resident in Urology The James Buchanan Brady Department of Urology The New York Hospital-Cornell Medical Center New York, N.Y. 2000-02 Fellow, Urologic Oncology Department of Urology Memorial Sloan Kettering Cancer Center New York, New York Academic positions: 7/01-6/02 Instructor in Urology Department of Urology Weill Medical College of Cornell University New York, N.Y. 7/02-6/08 Assistant Professor of Urology Clinical Director, Urologic Oncology Department of Urology Weill Medical College of Cornell University New York, N.Y. 7/08-Present Associate Professor of Urology Clinical Director, Urologic Oncology Weill Medical College of Cornell University New York, N.Y.
  • Guidelines for Printed Materials

    Guidelines for Printed Materials

    CONTINUING MEDICAL EDUCATION BRADY UROLOGY GRAND ROUNDS CONFERENCES April 6, 2020 to June 29, 2020 Weill Cornell Medical College 7:00-8:00am **All conferences will be held via Zoom** Peter Schlegel, M.D. Course Director April 6 Tumor Board Dr. Douglas Scherr, Dr. Jim Hu, Dr. Brian Robinson, Dr. Cora Sternberg 13 Combined Morbidity & Mortality, MSKCC/NYPQ/NYP-BM/NYPH Dr. Jaspreet Sandhu/Dr. Soo Jeong Kim Dr. Jerry Wang/Dr. Khushabu Kasabwala Dr. Alfred Winkler/Dr. Kiersten Craig Dr. Thomas McGovern/ Dr. Neal Patel 20 Morbidity & Mortality NYPH Quality and Patient Safety (QPS) Dr. Thomas McGovern & Dr. Neal Patel 27 Urology Diversity Lecture Transgender Medicine: Changing More than Hearts and Minds Dr. Marci L. Bowers Pelvic and Reconstructive Surgeon Mills-Peninsula Medical Center, Burlingame, CA May 4 Tumor Board Dr. Douglas Scherr, Dr. Jim Hu, Dr. Brian Robinson, Dr. Cora Sternberg 11 Russell W. Lavengood Visiting Professorship “Navigating Uncharted Waters: Boston Children’s Hospital Gender Surgery Program” David Diamond, M.D. Urologist-in-Chief, Boston Children’s Hospital Professor of Surgery, Harvard Medical School 18 Morbidity & Mortality NYPH Quality and Patient Safety (QPS) Dr. Thomas McGovern & Dr. Neal Patel 25 Memorial Day/No Rounds June 1 Tumor Board Dr. Douglas Scherr, Dr. Jim Hu, Dr. Brian Robinson, Dr. Cora Sternberg 8 “Challenges and Opportunities in Bladder Cancer Management 2020” Dr. Stephen A. Boorjian, Carl Rosen Professor in Urology Vice Chair of Research, Department of Urology Director, Urologic Oncology Fellowship, Mayo Clinic 15 “The Biology of Prostate Cancer Metastasis: Why Should We Care?” Dr. Ganesh S. Palapattu The George F.
  • USAV2109 Programbk V6

    USAV2109 Programbk V6

    Thank You MEETING SPONSORS: Urological Society for American Veterans (USAV) Annual Meeting SUNDAY, MAY 5, 2019 1:00 PM – 5:30 PM BALLROOM CDE HYATT REGENCY MCCORMICK PLACE Organizational support provided by: CHICAGO, IL DeSantis Management Group and the Society of Government Service Urologists GREETINGS USAV MEMBERS AND USERS of a new disposable 2019 USAV OFFICERS: flexible cystoscope. Powered by a notebook computer, this makes cysto mobile and "red bag" safe. Open a sterile package, EXECUTIVE COMMITTEE intubate, record and dispose it. Our mission is to bring you President: Jeffrey A. Jones, MD (Chief of Urology, Houston VA Med. Ctr. /Professor, Baylor College of Med.) effective ergonomic instruments for the endoscopic intubation Vice President/President Elect: Muta Issa, MD, MBA (Chief of Urology, Atlanta of the urinary tract. First and foremost you need visualize, second VA Med. Ctr. / Professor of Urology, Emory University) you need protection (disposable scope), third you need cost Secretary: Debora Moore, MD (SBYVAMC, Salisbury, NC) Treasurer: Krishnanath Gaitonde, MD (VHACIN) effectiveness and finally you need mobility by notebook power Member At Large: John Leppert, MD (Palo Alto, CA) with information storage. Picture a sterile disposable flexible OTHER POSITIONS: cystoscope with light, optics and storage in a notebook VA Member at Large, Liaison to SGSU Board: Mohammad Ramadan, MD computer and or I-Pad. Now you can do travel cystoscopy with USAV Representative, SGSU Board Member: Jeffrey Jones, MD less than five pounds of armamentarium in an attache or other AUA Liaison: Robert Moore, MD shoulder storage unit. Bylaws Committee: Robert Moore, MD, Muta Issa, MD, Jeffrey Jones, MD, Robert L.
  • Guidelines for Printed Materials

    Guidelines for Printed Materials

    CONTINUING MEDICAL EDUCATION BRADY UROLOGY GRAND ROUNDS CONFERENCES April 5, 2021 – June 28, 2021 Weill Cornell Medicine 7:00-8:00am **All conferences will be held via Zoom** Peter N. Schlegel, M.D. Course Director April 5 Tumor Board Dr. Douglas Scherr, Dr. Jim Hu, Dr. Brian Robinson, Dr. Cora Sternberg 12 “Prostate Cancer: Screening, Detecting and Treating smarter” Dr. Herbert Lepor Professor and Martin Spatz Chair of Urology, Professor of Pharmacology, NYU Grossman School of Medicine, Chief, Urology NYU Langone Health 19 R3 Research Year Plan Aaron Brant, M.D., Christina Sze, M.D., Jeffery Johnson, M.D. 26 “Transperineal Prostate Biopsy: What Convinced Me and What May or May Not Convince You.” Dr. John W. Davis Director, Urosurgical Prostate Program; Patient Safety/Quality Officer, Urology; UT Urology Residency Site Director; MD Anderson May 3 Tumor Board Dr. Douglas Scherr, Dr. Jim Hu, Dr. Brian Robinson, Dr. Cora Sternberg 10 “The Role of Surgery and Radiation in Metastatic Prostate Cancer” Dr. Brian Francis Chapin Associate Professor, Department of Urology, University of Texas MD Anderson Cancer Center 17 “10 things I hate about Prostate Cancer” Dr. Todd M. Morgan Professor and Chief of Urologic Oncology, University of Michigan 24 “Wellness and Surgery Education” Dr. Omar E. Bellorin-Marin, FACS Assistant Professor of Surgery, Minimally Invasive Surgery, GI Metabolic & Bariatric Surgery, Robotic Surgery, Department of Surgery, Weill Cornell Medicine 31 Memorial Day June 7 Tumor Board Dr. Douglas Scherr, Dr. Jim Hu, Dr. Brian Robinson, Dr. Cora Sternberg 14 “MRU in the Evaluation of Congenital Urinary Tract Dilation” Dr. Andrew J.
  • 2018 Star Reviewers for Urologic Oncology

    2018 Star Reviewers for Urologic Oncology

    Urologic Oncology: Seminars and Original Investigations 37 (2019) 229−262 2018 Star Reviewers for Urologic Oncology While the value of any medical journal depends upon the Sabine Brookman-May, Ph.D., M.D. quality of manuscripts received, the backbone of a journal’s LMU Munich, Dept. of Urology, Munich, Germany success is created by those who review manuscripts, iden- Clint Cary, M.D., M.P.H. tify problematic issues, make critical suggestions for Urology, Indiana University School of Medicine, Indianapolis, improvement, and assist the journal’s editors in deciding on Indiana, United States a manuscript’s disposition. This is no small task, and all too Edmund Chiong, M.B.B.S., Ph.D., F.R.C.S.Ed, F.R.C.S.I, F.A.M.S often it may feel thankless. Urology, National University Health System, Singapore, Singapore By acknowledging those reviewers whom our editors Nicholas Cost, M.D. have identified as “Star Reviewers,” Urologic Oncology Department of Surgery, Division of Urology, University of seeks to underscore the outstanding work that these Colorado School of Medicine, Aurora, CO, United States reviewers have done for the Journal over the course of this Chendil Damodaran, Ph.D. past year. We also wish to identify and thank all reviewers Urology, Univiersity of Louisville, Louisville, KY, United States for their excellent work and contributions in 2018. The Alexander Glaser, M.D. April 2019 issue of Urologic Oncology will therefore con- Department of Urology, Northwestern University, Chicago, IL, tinue its tradition of recognizing its reviewers such that all United States of our 2018 Reviewers and the Editors’ “Star Reviewers” Michael Gorin, M.D.